Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03506724 · ClinicalTrials.gov registry record · Phase 4
Response to Anti-hypertensives in Pregnant and Postpartum Patients
A Phase 4 study, sponsored by Icahn School of Medicine at Mount Sinai.
- Completed
- Registry status
- Phase 4
- Development phase
- 109
- Enrollment target
NCT03506724 is a Phase 4 study that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 109 participants.
The verdict
NCT03506724, a Phase 4 study, has completed, sponsored by Icahn School of Medicine at Mount Sinai.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 109 participants
- Enrollment target
Study Summary
In this study, the investigators will evaluate the blood pressure response to nifedipine and labetalol in pregnant and postpartum patients, who present with hypertensive disease in pregnancy with severe range blood pressure defined as greater than 160/110. These anti-hypertensives are first line therapy for management of severe range blood pressures in pregnancy and postpartum by the American Congress of Obstetricians and Gynecologist (ACOG). In addition at the Mount Sinai West site, the investigators will also analyze the ADRB1 and similar genes involved in beta blockade, genes involved in calcium channel blockade and other genes implicated in blood pressure response among pregnant and postpartum patients receiving labetalol and nifedipine. This analysis will be used to determine if a pharmacogenetic association exists between variant alleles in these receptors in the pregnant and postpartum population.
Interventions
- DRUG Labetalol
- DRUG Nifedipine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 109 participants |
| Start Date | 2017-09-11 |
| Est. Completion | 2019-04-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03506724
The ClinicalTrials.gov registry entry for NCT03506724 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 109 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Labetalol is the first listed.
NCT03506724 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03506724 about?
NCT03506724 is a clinical study titled "Response to Anti-hypertensives in Pregnant and Postpartum Patients". In this study, the investigators will evaluate the blood pressure response to nifedipine and labetalol in pregnant and postpartum patients, who present with hypertensive disease in pregnancy with severe range blood pressure defined as greater than 160/110. These anti-hypertensives are first line the...
What is the current status of trial NCT03506724?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 109 participants. The study started on 2017-09-11. Estimated completion is 2019-04-05.
What interventions are being tested in trial NCT03506724?
The interventions under investigation include: Labetalol (DRUG), Nifedipine (DRUG).
Who is sponsoring clinical trial NCT03506724?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.